800 related articles for article (PubMed ID: 26837745)
1. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
Ridker PM
Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory therapies for cardiovascular disease.
Ridker PM; Lüscher TF
Eur Heart J; 2014 Jul; 35(27):1782-91. PubMed ID: 24864079
[TBL] [Abstract][Full Text] [Related]
3. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
Ridker PM
Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
[TBL] [Abstract][Full Text] [Related]
4. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
Koenig W
Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
[TBL] [Abstract][Full Text] [Related]
5. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.
Ridker PM; Howard CP; Walter V; Everett B; Libby P; Hensen J; Thuren T;
Circulation; 2012 Dec; 126(23):2739-48. PubMed ID: 23129601
[TBL] [Abstract][Full Text] [Related]
6. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.
Ridker PM; MacFadyen JG; Glynn RJ; Bradwin G; Hasan AA; Rifai N
Eur Heart J; 2020 Aug; 41(31):2952-2961. PubMed ID: 32221587
[TBL] [Abstract][Full Text] [Related]
7. Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition.
Satish M; Agrawal DK
Transl Res; 2020 Jan; 215():75-85. PubMed ID: 31469975
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial.
Weickert TW; Jacomb I; Lenroot R; Lappin J; Weinberg D; Brooks WS; Brown D; Pellen D; Kindler J; Mohan A; Wakefield D; Lloyd AR; Stanton C; O'Donnell M; Liu D; Galletly C; Shannon Weickert C
Brain Behav Immun; 2024 Jan; 115():191-200. PubMed ID: 37848096
[TBL] [Abstract][Full Text] [Related]
9. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
Grebe A; Hoss F; Latz E
Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA
Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502
[TBL] [Abstract][Full Text] [Related]
11. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ;
Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077
[TBL] [Abstract][Full Text] [Related]
12. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker PM
Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Thuren T; Zalewski A; Libby P
Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
[TBL] [Abstract][Full Text] [Related]
14. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
[TBL] [Abstract][Full Text] [Related]
15. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
Ridker PM
Curr Atheroscler Rep; 2013 Jan; 15(1):295. PubMed ID: 23225175
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease.
Ridker PM; Rane M
Circ Res; 2021 May; 128(11):1728-1746. PubMed ID: 33998272
[TBL] [Abstract][Full Text] [Related]
17. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
[TBL] [Abstract][Full Text] [Related]
18. Inflammation, C-reactive protein, and atherothrombosis.
Ridker PM; Silvertown JD
J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
[TBL] [Abstract][Full Text] [Related]
19. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview.
Nidorf SM; Thompson PL
Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis.
Hettwer J; Hinterdobler J; Miritsch B; Deutsch MA; Li X; Mauersberger C; Moggio A; Braster Q; Gram H; Robertson AAB; Cooper MA; Groß O; Krane M; Weber C; Koenig W; Soehnlein O; Adamstein NH; Ridker P; Schunkert H; Libby P; Kessler T; Sager HB
Cardiovasc Res; 2022 Oct; 118(13):2778-2791. PubMed ID: 34718444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
